Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 373 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatic Impairment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

NCT03341884
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Ipatasertib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Miami, Florida • Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

NCT05935033
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

NCT01991678
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
Interventions
145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

NCT00162097
View directory record Official record
Conditions
HIV Infections, Hepatic Impairment
Interventions
efavirenz containing antiretroviral regimen
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • San Antonio, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

NCT01299454
View directory record Official record
Conditions
Schizophrenia
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Miami, Florida • Minneapolis, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

NCT05857644
View directory record Official record
Conditions
Liver Diseases, Hepatic Impairment
Interventions
PF-07923568
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

NCT07248839
View directory record Official record
Conditions
Healthy Volunteers, Hepatic Impairment
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

NCT06390410
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Lake Forest, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

NCT02245243
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Delafloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

NCT01767948
View directory record Official record
Conditions
Hepatic Impairment
Interventions
PCI-32765
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Costa Mesa, California • Orlando, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 13, 2026, 9:33 PM EDT
Terminated Phase 3 Interventional Results available

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

NCT02455167
View directory record Official record
Conditions
Hepatitis C
Interventions
Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

NCT06962332
View directory record Official record
Conditions
Hepatic Impairment, Moderate Hepatic Impairment
Interventions
Zanzalintinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

NCT04823702
View directory record Official record
Conditions
Impaired Hepatic Function
Interventions
Aldafermin
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 2 Interventional

AST-120 Used to Treat Mild Hepatic Encephalopathy

NCT00867698
View directory record Official record
Conditions
Mild Hepatic Encephalopathy
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT03765671
View directory record Official record
Conditions
Hepatic Impairment, Liver Disease, Pharmacokinetics
Interventions
Elafibranor
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional

Study of Telaprevir in Subjects With Hepatic Impairment

NCT00509210
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
telaprevir (VX-950)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2008 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

NCT02301104
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TAS-102
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Duarte, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042
View directory record Official record
Conditions
Hepatic Impairment, Hepatic Function
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

NCT05553470
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

NCT01419457
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
Favipiravir
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
19 Years to 69 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Not applicable Interventional

Dietary Interventions in Prediabetes

NCT01729078
View directory record Official record
Conditions
Impaired Fasting Glucose, Pre Diabetes, Liver Fat
Interventions
Dietary intervention
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 13, 2026, 9:33 PM EDT